


## DefiniGEN human iPS-derived FH hepatocytes



Familial hypercholesterolemia (FH) is an autosomal dominant disorder of lipoprotein metabolism caused mainly by mutations in the low-density lipoprotein receptor (LDLR) gene. Disease modelled Familial hypercholesterolemia hepatocytes (Def-HEP FH) are highly functional human hepatocytes derived using human induced pluripotent stem cell technology.


For the production of Def-HEP FH cells, fibroblasts are first reprogrammed into iPSC using the Nobel Prize winning technology developed by Yamanaka and colleagues. Horizon CRISPR gene-editing is then used to introduce a precise genetic mutation into the LDLR gene of an iPSC line. Def-HEP FH hepatocytes represent an optimized disease model for drug discovery applications and a principal tool for elucidating the underlying mechanisms of the disease.

### Genetic validation and cell viability

Def-HEP FH cells have been validated and verified for the E101K genetic mutation in the LDLR gene. Typical viabilities of the thawed hepatocytes are >70% upon receipt.

### Sequence data

cDNA sequencing (RT-PCR followed by TOPO cloning) was undertaken to determine the sequence of the cDNA expressed from the LDLR allele.



**Figure 1.** Sequence confirmation of LDLR E101K mutation in Def-HEP FH cells.

### Advantages

**Standardized cell product** containing >98% human hepatocyte cells producing reproducible and biologically relevant data


**Disease circuit verification** LDL uptake is significantly impaired in Def-HEP FH cells

**Optimized work flow** we can deliver industrial quantities of cryopreserved cells to client specification


## Functional test

The in vivo functional implications of LDL receptor deficiency are conserved in our model, as shown by immunostaining. The results demonstrate that Def-HEP FH hepatocytes have an impaired ability to incorporate LDL (Figure 2). Receptor-specific binding of Dil-LDL is followed by internalization of the bound complex and lysosomal hydrolysis of the ligand. An increase in the fluorescence intensity per cell is hence used as a measure of Dil-LDL uptake and, implicitly, as an indication of LDLR presence. These findings signify that CRISPR generated disease-specific human iPS cells can successfully be used to model Familial Hypercholesterolemia.

**Def-HEP WT**




**Def-HEP FH**



**Figure 2.** Quantification of intracellular A1AT polymers and intercellular total A1AT secretion in Def-HEP A1ATD cells. Primary human hepatocytes (PHH) and hepatocellular liver carcinoma cells (Hep G2) are used as internal controls.

## LDL receptor analysis

Def-HEP FH cells demonstrate an impaired ability to take up LDL cholesterol relative to the WT isogenic control.



**Figure 3.** Quantitative LDL receptor assays based on fluorescent Dil-LDL internalization have demonstrated that Def-HEP FH iPSC-derived hepatocytes have a significantly impaired ability to incorporate LDL relative to the isogenic control Def-HEP WT over a range of LDL substrate ranges.

## References

Modelling Familial Hypercholesterolemia using human isogenic induced pluripotent stem cells. Diaz A, Soares F, Santos R, Jhaveri K, Schofield C, Lowe C, Yeo M. ISSCR 2016. June 22-25.

Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. Rashid ST, Lomas DA, Vallier L et al. J Clin Invest. 2010 Sep;120(9):3127-36.